# Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

> **NCT00624182** · PHASE1 · SUSPENDED · sponsor: **Akita University Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Bile Duct Cancer

## Interventions

- **BIOLOGICAL:** Peptide vaccine for URLC10
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00624182
- **Lead sponsor:** Akita University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2008-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2015-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624182, "Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00624182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*